仟源医药(300254.SZ):盐酸氨溴索分散片通过一致性评价
格隆汇1月16日丨仟源医药(300254.SZ)公布,公司近日收到了国家药品监督管理局核准签发的“盐酸氨溴索分散片”的《药品补充申请批件》,该药品通过仿制药质量与疗效一致性评价。
“盐酸氨溴索分散片”适用于痰液粘稠而不易咳出者,服用方法多样化,可加水分散后口服,也可含于口中吮服或吞服。截至本公告披露日,公司为全国首家该品种以“分散片”剂型通过一致性评价的企业,该品种现已列入国家医保目录和国家基本药物目录。
根据国家相关政策,通过一致性评价的药品品种,在药品招标、医保支付层面等方面获得一定支持。因此公司“盐酸氨溴索分散片”通过一致性评价,有利于提高产品市场竞争力,并对公司的经营产生积极的影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.